Jpmorgan Chase & CO Keros Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 55,410 shares of KROS stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,410

Previous 62,644 11.55%

Holding current value

$2.53 Million

Previous $2.49 Million 47.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$41.26 - $70.48 $298,474 - $509,852	-7,234 Reduced 11.55%	55,410 $3.67 Million
Q4 2023 Feb 12, 2024	BUY	$27.12 - $41.05 $259,674 - $393,053	9,575 Added 18.04%	62,644 $2.49 Million
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $738,075 - $1.01 Million	23,379 Added 78.74%	53,069 $1.69 Million
Q2 2023 Aug 11, 2023	BUY	$37.26 - $51.01 $233,620 - $319,832	6,270 Added 26.77%	29,690 $1.19 Million
Q1 2023 May 18, 2023	BUY	$41.44 - $59.32 $962,941 - $1.38 Million	23,237 Added 12697.81%	23,420 $1 Million

Q1 2023 May 11, 2023	SELL	$41.44 - $59.32 $1.71 Million - $2.45 Million	-41,298 Reduced 99.56%	183 $7,000
Q4 2022 Feb 13, 2023	BUY	$39.45 - $51.77 $935,359 - $1.23 Million	23,710 Added 133.42%	41,481 $1.99 Million
Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $70,806 - $102,185	2,547 Added 16.73%	17,771 $669,000
Q2 2022 Aug 11, 2022	SELL	$26.03 - $67.04 $580,573 - $1.5 Million	-22,304 Reduced 59.43%	15,224 $420,000
Q1 2022 May 11, 2022	BUY	$42.12 - $59.36 $182,337 - $256,969	4,329 Added 13.04%	37,528 $2.04 Million
Q4 2021 Feb 10, 2022	BUY	$36.95 - $62.89 $838,654 - $1.43 Million	22,697 Added 216.12%	33,199 $1.94 Million
Q3 2021 Nov 12, 2021	BUY	$29.27 - $43.71 $307,393 - $459,042	10,502 New	10,502 $415,000

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Keros Therapeutics, Inc. Transaction History